0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

Paolo Prandoni, MD, PhD; Anthonie W.A. Lensing, MD, PhD; Alberto Cogo, MD, PhD; Stefano Cuppini, MD; Sabina Villalta, MD; Mariarosa Carta, MD; Anna M. Cattelan, MD; Paola Polistena, MD; Enrico Bernardi, MD; and Martin H. Prins, MD, PhD
[+] Article and Author Information

From the University Hospital of Padua, Padua, Italy, and the Academic Medical Center, Amsterdam, the Netherlands. Requests for Reprints: Anthonie W.A. Lensing, MD, PhD, Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, F-4, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands. Current Author Addresses: Drs. Prandoni, Cogo, Cuppini, Villalta, Carta, Cattelan, Polistena, and Bernardi: Ospedale Civile Pathologia Medica 11, via Giustiniani 2, 35128 Padua, Italy.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;125(1):1-7. doi:10.7326/0003-4819-125-1-199607010-00001
Text Size: A A A

Background: In patients who have symptomatic deep venous thrombosis, the long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae have not been well documented.

Objective: To determine the clinical course of patients during the 8 years after their first episode of symptomatic deep venous thrombosis.

Design: Prospective cohort study.

Setting: University outpatient thrombosis clinic.

Patients: 355 consecutive patients with a first episode of symptomatic deep venous thrombosis.

Measurements: Recurrent venous thromboembolism, the post-thrombotic syndrome, and death. Potential risk factors for these outcomes were also evaluated.

Results: The cumulative incidence of recurrent venous thromboembolism was 17.5% after 2 years of follow-up (95% CI, 13.6% to 22.2%), 24.6% after 5 years (CI, 19.6% to 29.7%), and 30.3% after 8 years (CI, 23.6% to 37.0%). The presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively). The cumulative incidence of the post-thrombotic syndrome was 22.8% after 2 years (CI, 18.0% to 27.5%), 28.0% after 5 years (CI, 22.7% to 33.3%), and 29.1% after 8 years (CI, 23.4% to 34.7%). The development of ipsilateral recurrent deep venous thrombosis was strongly associated with the risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). Survival after 8 years was 70.2% (CI, 64.7% to 75.6%). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1).

Conclusion: Patients with symptomatic deep venous thrombosis, especially those without transient risk factors for deep venous thrombosis, have a high risk for recurrent venous thromboembolism that persists for many years. The post-thrombotic syndrome occurs in almost one third of these patients and is strongly related to ipsilateral recurrent deep venous thrombosis. These findings challenge the widely adopted use of short-course anticoagulation therapy in patients with symptomatic deep venous thrombosis.

Figures

Grahic Jump Location
Figure 1. The dashed lines represent the 95% CIs.
The cumulative incidence of recurrent venous thromboembolism in patients with a first episode of symptomatic deep venous thrombosis.
Grahic Jump Location
Grahic Jump Location
Figure 3. The dashed lines represent the 95% CIs.
Survival in patients with a first episode of symptomatic deep venous thrombosis.
Grahic Jump Location
Grahic Jump Location
Figure 2. The dashed lines represent the 95% CIs.
The cumulative incidence of severe cases and all cases of the post-thrombotic syndrome (PTS) in patients with a first episode of symptomatic deep venous thrombosis.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
The diagnosis and treatment of venous thromboembolism. Hematology Am Soc Hematol Educ Program 2013;2013():457-63.
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)